Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cybin Inc. (CYBN)

0.3999   -0.01 (-2.46%) 01-27 16:00
Open: 0.41 Pre. Close: 0.41
High: 0.41 Low: 0.38
Volume: 1,210,223 Market Cap: 71(M)

Technical analysis

as of: 2023-01-27 4:43:40 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.57     One year: 0.72
Support: Support1: 0.27    Support2: 0.22
Resistance: Resistance1: 0.48    Resistance2: 0.62
Pivot: 0.44
Moving Average: MA(5): 0.4     MA(20): 0.41
MA(100): 0.47     MA(250): 0.63
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 26     %D(3): 30.8
RSI: RSI(14): 49.7
52-week: High: 1.15  Low: 0.26
Average Vol(K): 3-Month: 1,318 (K)  10-Days: 1,550 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CYBN ] has closed above bottom band by 28.2%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.41 - 0.41 0.41 - 0.41
Low: 0.37 - 0.38 0.38 - 0.38
Close: 0.4 - 0.4 0.4 - 0.4

Company Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Headline News

Thu, 26 Jan 2023
PsychedelicNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American ... - MarketWatch

Thu, 26 Jan 2023
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry - Yahoo Finance

Thu, 26 Jan 2023
Cybin to Host Virtual R&D Day on February 28, 2023 - Business Wire

Wed, 18 Jan 2023
PsychedelicNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO ... - MarketWatch

Wed, 18 Jan 2023
Psychedelic Stocks in Focus (LOBEF,ATAI,CMPS,MNMD,SEEL,CYBN) - BP Journal

Wed, 11 Jan 2023
Will Cybin Inc (CYBN) Beat the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 160 (M)
Shares Float 113 (M)
% Held by Insiders 21.6 (%)
% Held by Institutions 16.9 (%)
Shares Short 2,960 (K)
Shares Short P.Month 2,690 (K)

Stock Financials

EPS -0.31
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.62
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.01
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -38 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -1.3
PEG Ratio 0
Price to Book value 0.64
Price to Sales 0
Price to Cash Flow -1.7

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.